HELSINKI/LONDON, May 23 (Reuters) - GlaxoSmithKline Plc's H1N1 pandemic flu shot may put adults at higher risk of developing narcolepsy, not only children as previous studies found, Finland's National ...
Stocktwits on MSN
HRMY stock rises on fresh FDA approval for Wakix tablets in children but Wall Street eyes further rally
Wakix was first approved by the FDA for adult narcolepsy patients in 2019 and for pediatric narcolepsy patients in 2024. ・Harmony has an exclusive license from France’s Bioprojet to develop, ...
With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.
New FDA approval for Wakix (pitolisant) allows for the treatment of cataplexy in pediatric narcolepsy patients.
First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has approved a supplemental new drug application ...
The company said Tuesday that the FDA greenlit a supplemental new drug application for Wakix, a treatment for cataplexy, a narcolepsy symptom characterized by sudden muscle weakness, in pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results